Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 6
1994 4
1995 2
1996 3
1997 2
1998 23
1999 33
2000 47
2001 53
2002 84
2003 83
2004 102
2005 102
2006 104
2007 121
2008 102
2009 103
2010 118
2011 116
2012 93
2013 104
2014 109
2015 122
2016 97
2017 111
2018 97
2019 96
2020 110
2021 121
2022 110
2023 117
2024 63

Text availability

Article attribute

Article type

Publication date

Search Results

2,344 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Hansen RA, Gartlehner G, Webb AP, Morgan LC, Moore CG, Jonas DE. Hansen RA, et al. Clin Interv Aging. 2008;3(2):211-25. Clin Interv Aging. 2008. PMID: 18686744 Free PMC article. Review.
Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and rivastigmine. Results are conflicting; two studies suggest no differences in efficacy between compared drugs, while one study found donepezil to be more efficacio …
Three open-label trials and one double-blind randomized trial directly compared donepezil with galantamine and rivastigmine. Results …
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Marucci G, Buccioni M, Ben DD, Lambertucci C, Volpini R, Amenta F. Marucci G, et al. Neuropharmacology. 2021 Jun 1;190:108352. doi: 10.1016/j.neuropharm.2020.108352. Epub 2020 Oct 6. Neuropharmacology. 2021. PMID: 33035532 Free article. Review.
The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its hepatotoxicity. According to mechanism of action the ChE-Is are classified as short-acting or reversible agents such as tacrine, donepezil, a …
The ChE-Is currently available in the market are donepezil, rivastigmine and galantamine as tacrine is no longer in use, due to its h …
Rivastigmine: in Parkinson's disease dementia.
Siddiqui MA, Wagstaff AJ. Siddiqui MA, et al. CNS Drugs. 2006;20(9):739-47; discussion 748-50. doi: 10.2165/00023210-200620090-00003. CNS Drugs. 2006. PMID: 16953649 Review.
The beneficial effects of rivastigmine observed in the double-blind trial were generally maintained in a 24-week extension of this study in which all patients received active treatment; placebo recipients who switched to rivastigmine also experienced improvements in …
The beneficial effects of rivastigmine observed in the double-blind trial were generally maintained in a 24-week extension of this st …
Rivastigmine-Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors.
Wu J, Tan Z, Pistolozzi M, Tan W. Wu J, et al. Molecules. 2023 Dec 22;29(1):72. doi: 10.3390/molecules29010072. Molecules. 2023. PMID: 38202655 Free PMC article.
Selective butyrylcholinesterase inhibitors are considered promising drug candidates for the treatment of Alzheimer's disease. In this work, one rivastigmine-bambuterol hybrid (MTR-1) and fourteen of its analogues were synthesized, purified, and characterized. ...
Selective butyrylcholinesterase inhibitors are considered promising drug candidates for the treatment of Alzheimer's disease. In this work, …
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Kandiah N, Pai MC, Senanarong V, Looi I, Ampil E, Park KW, Karanam AK, Christopher S. Kandiah N, et al. Clin Interv Aging. 2017 Apr 18;12:697-707. doi: 10.2147/CIA.S129145. eCollection 2017. Clin Interv Aging. 2017. PMID: 28458525 Free PMC article. Review.
Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer's disease (AD) and Parkinson's disease dementia (PDD). ...Additionally, we review the evidence supporting the use of dual AChE-BuChE inhibitory activit …
Several studies have demonstrated clinical benefits of sustained cholinesterase inhibition with rivastigmine in Alzheimer's disease ( …
Rivastigmine for vascular cognitive impairment.
Birks J, McGuinness B, Craig D. Birks J, et al. Cochrane Database Syst Rev. 2013 May 31;(5):CD004744. doi: 10.1002/14651858.CD004744.pub3. Cochrane Database Syst Rev. 2013. PMID: 23728651 Review.
Significantly higher rates of vomiting, nausea, diarrhoea and anorexia and withdrawals from treatment were noted in the participants randomized to rivastigmine compared with placebo (withdrawals rivastigmine 90/365, placebo 48/345, OR 2.02, 95% CI 1.38 to 2.98) (wit …
Significantly higher rates of vomiting, nausea, diarrhoea and anorexia and withdrawals from treatment were noted in the participants randomi …
Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.
Grossberg GT, Sadowsky C, Olin JT. Grossberg GT, et al. Int J Clin Pract. 2010 Apr;64(5):651-60. doi: 10.1111/j.1742-1241.2009.02330.x. Epub 2010 Jan 19. Int J Clin Pract. 2010. PMID: 20102418 Review.
Most patients experienced no, slight or mild application-site skin reactions. De novo patients or those taking oral rivastigmine or donepezil may tolerate a switch to rivastigmine patch. ...The rivastigmine patch provides a viable treatment option for patient …
Most patients experienced no, slight or mild application-site skin reactions. De novo patients or those taking oral rivastigmine or d …
Rivastigmine for dementia in people with Down syndrome.
Mohan M, Bennett C, Carpenter PK. Mohan M, et al. Cochrane Database Syst Rev. 2009 Jan 21;2009(1):CD007658. doi: 10.1002/14651858.CD007658. Cochrane Database Syst Rev. 2009. PMID: 19160344 Free PMC article. Review.
Rivastigmine can improve cognitive function and slow the decline of AD in the general population over time. ...We contacted the manufacturers of rivastigmine as well as experts in the field, to ask about reports of unpublished or ongoing trials. ...
Rivastigmine can improve cognitive function and slow the decline of AD in the general population over time. ...We contacted the manuf …
Rivastigmine. A review of its use in Alzheimer's disease.
Spencer CM, Noble S. Spencer CM, et al. Drugs Aging. 1998 Nov;13(5):391-411. doi: 10.2165/00002512-199813050-00005. Drugs Aging. 1998. PMID: 9829166 Review.
Rivastigmine (SDZ ENA 713) is a carbamylating, long-acting reversible and noncompetitive carbamate acetylcholinesterase inhibitor that is indicated as an oral treatment for patients with mild to moderately severe Alzheimer's disease. ...Individual results of the 2 pivotal …
Rivastigmine (SDZ ENA 713) is a carbamylating, long-acting reversible and noncompetitive carbamate acetylcholinesterase inhibitor tha …
Rivastigmine transdermal patch: role in the management of Alzheimer's disease.
Guay DR. Guay DR. Consult Pharm. 2008 Aug;23(8):598-609. doi: 10.4140/tcp.n.2008.598. Consult Pharm. 2008. PMID: 19032006 Review.
STUDY SELECTION AND DATA EXTRACTION: All studies evaluating any aspect of TD rivastigmine, including in vivo animal experimentation. DATA SYNTHESIS: Rivastigmine is the first acetylcholinesterase inhibitor to be marketed in a TD formulation. ...For patients with swa …
STUDY SELECTION AND DATA EXTRACTION: All studies evaluating any aspect of TD rivastigmine, including in vivo animal experimentation. …
2,344 results

Searches related to "rivastigmine"